S-1/A: Cardiff Lexington Corp Files Amendment No. 2 to Form S-1/A, Eyes NYSE American Uplisting

Cardiff Lexington Corporation files an amendment to its Form S-1/A registration statement, aiming to offer 1,600,000 shares of common stock and uplist to NYSE American under the symbol CDIX.

Summary

• Cardiff Lexington Corporation has filed Amendment No. 2 to its Form S-1/A registration statement with the SEC.
• The company intends to offer 1,600,000 shares of common stock to the public, with an estimated offering price between $4.00 and $6.00 per share.
• The company is seeking to uplist its common stock to NYSE American under the ticker symbol CDIX, contingent upon the closing of the offering.
• The company plans to use the net proceeds of approximately $6.7 million (or $7.8 million if the underwriters exercise their over-allotment option in full) for working capital and general corporate purposes.
• The company's revenue for the year ended December 31, 2023, was $11,853,266, with a net income of $3,028,394.
• The company's primary focus is on the healthcare sector and real estate.
• The company operates eleven healthcare facilities, most of which were opened in the last twenty-four months.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report.
• The company's officers and directors own a significant percentage of the company's outstanding voting securities.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company shows improved financial performance in 2023, the going concern warning and identified material weaknesses in internal controls raise concerns. The planned uplisting and capital raise are positive steps, but the risks associated with acquisitions and market volatility temper the overall outlook.

Positives

• The company achieved net income of $3,028,394 for the year ended December 31, 2023, a significant improvement from the net loss of $5,429,521 in 2022.
• The company's revenue increased by 10.85% to $11,853,266 for the year ended December 31, 2023.
• The company is expanding its healthcare business, operating eleven facilities.
• The company is seeking to uplist to NYSE American, which could increase its visibility and access to capital.

Negatives

• The report of the company's independent registered public accounting firm included a going concern explanatory paragraph.
• The company's officers and directors own a significant percentage of the company's outstanding voting securities which could reduce the ability of minority stockholders to effect certain corporate actions.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's acquisition strategy exposes it to substantial risk.
• The company may not be able to effectively integrate the businesses that it acquires.
• The company faces competition for businesses that fit its acquisition strategy.
• The company may not be able to successfully fund acquisitions due to the unavailability of equity or debt financing on acceptable terms.
• The market price of the company's common stock may be highly volatile.
• The company's management has broad discretion as to the use of the net proceeds from this offering.
• The company may not be able to satisfy NYSE Americans listing requirements or maintain a listing of its common stock on NYSE American.

Future Outlook

The company expects to maximize organic growth by deploying increased working capital to expand utilization at current locations, open additional locations, and consider select synergistic acquisitions in the healthcare sector.

Industry Context

The announcement reflects a company in the healthcare sector seeking to expand its operations and improve its financial standing through a public offering and uplisting, which is a common strategy for growth-oriented companies in fragmented industries.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To assess the results in the context of global benchmarks, more specific details are needed, such as revenue growth compared to industry averages, profitability metrics compared to competitors like HCA Healthcare or Universal Health Services, and debt levels compared to similar-sized healthcare companies.
• Without these specifics, a comprehensive assessment against industry standards is not possible.

Legal Proceedings

• Absolute Medical Group, LLC filed charges against the company for breach of contract.
• The company filed a complaint in Idaho against Mark Adams, seeking damages for breach of contract, breach of fiduciary duties, and conversion.
• Sherri Gastelum filed a complaint against the company and its lender for fraud and breach of contract in connection with the 2018 acquisition and subsequent sale of Platinum Tax.

Related Party Transactions

• The company has obtained short-term advances from the Chairman of the Board that are non-interest bearing and due on demand.
• On August 25, 2023, the company issued a convertible promissory note in the principal amount of $5,000 to Alex Cunningham, its Chief Executive Officer.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's ability to execute its business plan and acquire additional businesses depends on its ability to obtain additional financing.
• The company's performance is dependent on its ability to recruit and retain quality physicians, nurses, and medical support staff.

Next Steps

• The company intends to apply for the listing of its common stock on NYSE American.
• The company will determine the final offering price and number of shares based on market conditions.
• The company will use the net proceeds for working capital and general corporate purposes, which could include future acquisitions.

Key Dates

Keywords

Cardiff Lexington Corporation, common stock, NYSE American, offering, healthcare, acquisition, preferred stock, convertible notes, financial results, risk factors